Navigation Links
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
Date:6/29/2010

nt adverse events or observations of hypoglycemia. The most common adverse event was mild injection site reactions.  

"We have demonstrated that our PTP-1B inhibitor has a very attractive profile in two Phase 2 studies in patients with type 2 diabetes.  A novel insulin sensitizer that reduces high blood glucose without resulting in hypoglycemia, reduces LDL-cholesterol and decreases weight would be a significant advance in the treatment of type 2 diabetes," said Sanjay Bhanot, M.D., Ph.D., Vice President of Metabolics and Translational Medicine at Isis.  "In this study, we observed reductions in multiple measures of glucose control that were consistent with our expectations for a 13-week study. We believe that with longer-term treatment we should also see reductions in longer-term measures of glucose control.  We are excited to continue to move this program forward and to evaluate PTP-1B inhibition in longer studies in combination with other commonly prescribed type 2 diabetes drugs."

In the oral presentation titled "First Proof of Pharmacology of a Novel Glucagon Receptor Antisense Drug in Humans," Dr. Bhanot presented the results of a Phase 1 study on ISIS-GCGRRx. The study, which included a glucagon challenge that doubled both plasma glucagon and glucose levels, produced the following results:

  • Statistically significant improvement in blood glucose levels and reduced liver glucose production following the glucagon challenge at a dose of 400 mg/week
  • No clinically significant adverse events or observations of hypoglycemia. The most common adverse event was mild injection site reactions.  

"In our Phase 1 study of ISIS-GCGRRx we achieved reductions in blood glucose following a glucagon challenge.  This re
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hospira Highlights a Year of Significant Progress at Its 2010 Annual Meeting of Shareholders
2. Abbott 2009 Global Citizenship Report Highlights Companys Progress in Redefining Responsibility
3. DUSA Pharmaceuticals, Inc.(R) to Host First Quarter 2010 Corporate Highlights and Financial Results Conference Call
4. LightLab Highlights OCT Market Leadership at the Society for Cardiovascular Angiography and Interventions
5. Abbott Annual Meeting Highlights Continued Strong Performance in 2009; Sustained Growth in 2010
6. Bionovo Announces 2009 Highlights and Year-End Financial Results
7. Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010
8. New Publication Highlights 2-Year Durability and Effectiveness of Macroplastique(R)
9. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
10. Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
11. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Alvarado Hospital unveiled its new facility ... & Joint Institute. The institute is entirely devoted ... surgery and joint replacement. The Spine & Joint ... experience-focused approach. For example, patients are encouraged to ... than patient gowns. "From the ...
(Date:7/29/2015)... LAKE FOREST, Calif. , July 29, ... ) ("Cryoport" or the "Company"), the leading ... the life sciences industry, serving markets including ... organizations, vaccine manufacturers, animal health, and reproductive ... completed the sale of common stock and warrants ...
(Date:7/29/2015)...  Ortho-Clinical Diagnostics, Inc. (OCD) today announced the presentation ... address a range of important tests for clinical labs ... The scientific posters will be delivered during the 2015 ... held July 26 - 30 in Atlanta, ... is emerging stronger than ever since becoming a stand-alone ...
Breaking Medicine Technology:The Alvarado Spine & Joint Institute Opens July 30 in San Diego 2Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 2Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 3
... DIEGO, Feb. 11, 2011 Conatus Pharmaceuticals Inc. today ... Preferred Stock private placement financing.  This financing was led ... and included participation by existing investors; Aberdare Ventures, Advent ... Roche Venture Fund.  Conatus will use the proceeds to ...
... LOS ANGELES, Feb. 11, 2011 Nationally-acclaimed researcher and ... speech at the 11th National Conference on Cancer Nursing ... potentially deadly infections they were supposed to prevent. ... needleless IV connector devices with silver coated or silver ...
Cached Medicine Technology:Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing 2Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research 2
(Date:7/30/2015)... , ... July 30, 2015 , ... ... at multinational organizations and NGO’s, according to a new survey by leading international ... that property damage and employee medical expenses represented the largest sources of financial ...
(Date:7/30/2015)... ... July 30, 2015 , ... After a three year trial designed to ... commonly known as the “bionic eye,” researchers have determined the trial to be a ... patients facing or already affected by complete vision loss as a result of Retinitis ...
(Date:7/30/2015)... ... July 30, 2015 , ... According to Chicago ... find a complete removable denture acceptable. The demand for dental implants is rising ... less expensive, immediate loading techniques will have the ability to offer the patient ...
(Date:7/30/2015)... ... 2015 , ... When trying to gain weight, many people place a lot of focus on the different types ... to be consumed. However, another key component to successful weight gain is knowing when ... this, CB-1 Weight Gainer gives three tips on when to eat to gain weight. ...
(Date:7/30/2015)... ... ... PeopleKeys, a company with over 30 years of experience in behavioral analysis, ... the newest installment in their popular DISC for the Real World series, will air ... webinar is intended for people interested in training others to use DISC behavioral analysis ...
Breaking Medicine News(10 mins):Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 3Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 2Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 3Health News:PeopleKeys to Air “Managing Stress: Train the Trainer” DISC Webinar 2
... WASHINGTON, April 8, 2008 The following is a,statement ... Governor Ted Strickland and Ohio legislators have abandoned ... their underhanded actions today to,raid funds from the Ohio ... to come more Ohio children will become addicted to,tobacco, ...
... Important to Protect Animal, Human Health, WASHINGTON, ... today launched its newly designed "Keeping Animals Healthy",website ... important,role of public policy in providing animal medicines ... are becoming more aware of the relationship between ...
... Filed in ... ... KV Pharmaceutical,Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical,company that ... pharmaceutical,products, announced today that it has reached a comprehensive settlement,agreement ...
... Clinical Trial Results on Preoperative Chemotherapy in Early Breast ... no better than six cycles in women with early ... according to data from a randomized controlled trial. Additionally, ... cycles of one drug combination did not benefit from ...
... of the main obstacles towards progress in the developing ... that have not been seriously addressed by the public ... new book, Forgotten People, Forgotten Diseases, published by ASM ... the world have too long been ignored. Parasitic ...
... Ultravist(R) are part of Amerinet,s Portfolio of ... Contracted ... HealthCare,Pharmaceuticals Inc., a leader in diagnostic imaging, announced today that,the ... to make,Magnevist(R) (gadopentetate dimeglumine) injection and Ultravist(R),(iopromide) injection available to ...
Cached Medicine News:Health News:KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation 2Health News:KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation 3Health News:Other highlights in the April 8 JNCI 2Health News:Other highlights in the April 8 JNCI 3Health News:Other highlights in the April 8 JNCI 4Health News:Forgotten diseases key to lifting developing world from poverty, destitution and despair 2Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 2Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 3Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 4
... The new Primus PDQ Plus for the determination ... and accurate results. The PDQ Plus is a ... on-line barcode reading for the ultimate in safety ... affinity which is well known to be interference-free ...
Micromat II Hemoglobin A1c instrument is an easy-to-use, accurate and precise instrument with an requirement of only 10 L of capillary or venous sample....
... Cascade M-4 is a manual hemostasis ... routine clotting assays - PTs, aPTTs, ... for easy, inexpensive, low-volume testing, this ... big on features, offering time and ...
... a fully automated, benchtop coagulation workstation ... immunological assays in true random access ... sample management offers high throughput and ... the need to interrupt current testing. ...
Medicine Products: